title: Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.
abstract: The mechanism of inactivation of cytochrome P450 2B1 (CYP2B1) by 4-tert-butylphenylacetylene (BPA) has been characterized previously to be caused by the covalent binding of a reactive intermediate to the apoprotein rather than heme destruction (J Pharmacol Exp Ther 331:392-403, 2009). The identification of a BPA-glutathione conjugate and the increase in the mass of the BPA-adducted apoprotein have indicated that the mass of adduct is 174 Da, equivalent to the mass of BPA plus one oxygen atom. To identify the adducted residue, BPA-inactivated CYP2B1 was digested with trypsin, and the digest was then analyzed by using capillary liquid chromatography with a LTQ linear ion trap mass spectrometer as the detector. A mass shift of 174 Da was used for a SEQUEST database search. The tandem mass spectrometry fragmentation of the modified peptide and the identity of modified residue were determined. The results revealed a mass increase of 174 Da for the peptide sequence (296)FFAGTSSTTLR(308) in the I-helix of CYP2B1 and that the site of adduction formation is Thr302. Homology modeling and ligand docking studies showed that BPA binds in close proximity to both the heme iron and Thr302 with the distances being 2.96 and 3.42 A, respectively. The identification of Thr302 in the CYP2B1 active site as the site of covalent modification leading to inactivation by BPA supports previous hypotheses that this conserved Thr residue may play a crucial role for various functions in P450s.
authors.affiliation: Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109-5632, USA.
authors.forename: Hsia-lien
authors.initials: HL
authors.lastname: Lin
authors.forename: Haoming
authors.initials: H
authors.lastname: Zhang
authors.forename: Monica
authors.initials: M
authors.lastname: Jushchyshyn
authors.forename: Paul F
authors.initials: PF
authors.lastname: Hollenberg
mesh_terms: D000114:Acetylene / Q000031:analogs & derivatives* / Q000494:pharmacology; D000595:Amino Acid Sequence; D053801:Capillary Electrochromatography; D020134:Catalytic Domain / Q000187:drug effects; D019362:Cytochrome P-450 CYP2B1 / Q000737:chemistry / Q000187:drug effects*; D030562:Databases, Protein; D004926:Escherichia coli; D006418:Heme / Q000737:chemistry / Q000378:metabolism; D006868:Hydrolysis; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011485:Protein Binding; D011487:Protein Conformation; D011994:Recombinant Proteins / Q000378:metabolism; D013057:Spectrum Analysis; D013912:Threonine / Q000737:chemistry / Q000187:drug effects*; D014357:Trypsin
chemical_list: C545118:4-tert-butylphenylacetylene; D011994:Recombinant Proteins; D013912:Threonine; D006418:Heme; D019362:Cytochrome P-450 CYP2B1; D014357:Trypsin; D000114:Acetylene